Compare Amylx Pharmaceuticals Inc (AMLX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.18 (market cap $1.98B), while United Microelectronics Corp trades at $23.2 (market cap $61.20B). The key difference: United Microelectronics Corp is far larger — about 30.9× Amylx Pharmaceuticals Inc's market cap, and United Microelectronics Corp pays a 1.69% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | UMC | |
|---|---|---|
Market Cap | $1.98B | $61.20B |
Sector | Health | Technology |
52-Week High | $18.70 | $28.02 |
52-Week Low | $7.64 | $6.58 |
Enterprise Value | $1.70B | $58.77B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
UMC trades at $24.34, down 2.09% today, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $237.55B in 2025, though net income margin compressed to 16.99%. Recent June 2026 sales rose 22.85% year-over-year, and the company launched a 14nm eHV FinFET platform for display drivers. Analyst consensus is mixed with 27% buy ratings, while institutional sentiment leans positive amid AI and automotive chip demand.
Outlook: UMC benefits from specialty semiconductor demand, but high P/E of 39.52 and margin pressures pose valuation risks. Earnings beats and dividend payments support income investors, yet competition and cyclical industry volatility require caution for growth-focused shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
